1st-line treatment of HTN; can be used as the sole agent to control
BP in the majority of patients. Symptomatic treatment of chronic stable angina, used alone or in combination w/ other antianginal drugs. Confirmed or suspected vasospastic angina, as monotherapy, or in combination w/ other antianginal drugs. Reduce risk of hospitalization due to angina & risk of a coronary revascularization procedure in patients w/ recently documented CAD by angiography & w/o heart failure or an ejection fraction <40%,
Increased simvastatin exposure. Bioavailability may be increased by grapefruit juice. Plasma conc may be increased by strong CYP3A4 inhibitors of (eg, ketoconazole, itraconazole, ritonavir). Increased risk of hypotension w/ clarithromycin. Plasma conc may be decreased by CYP3A4 inducers (eg, rifampicin, St. John's Wort). Risk of increased tacrolimus blood levels. May increase exposure of mechanistic target of rapamycin inhibitors.